Ivim Health Review 2026: Pricing, Membership Fee & How Trimi Compares

Ivim Health Pricing in 2026: The Full Picture

Ivim uses a two-component pricing model: the medication plan plus a mandatory membership. Per Ivim's published pricing as of August 2026, compounded semaglutide starts at $75/month, compounded tirzepatide at $133/month, and compounded liraglutide at $249/month. All compound programs require upfront payment for the plan length you choose — 1, 2, 4, or 6-month terms on its GLP-1 ID program, with 6- and 12-month packages sold on its pricing page — and the $74.99/month membership (first month free) is required for the full duration of that plan.

Two things follow from that structure. First, the number in the headline is not the number on your card: at starting rates, semaglutide is roughly $150/month all-in and tirzepatide roughly $208/month all-in once membership billing begins. Second, “starting at” is doing real work — Ivim's rates vary by plan length, and shorter packages cost more per month (a 6-month semaglutide package runs $600, about $100/month, versus the $75/month rate on the 12-month package), so confirm the exact price for your plan and dose before you pay. Our guide to what compounded semaglutide actually costs breaks down why these billing models make headline prices hard to compare.

Run the 12-month math at published starting rates and the gap becomes concrete. Ivim's semaglutide path totals roughly $1,725 in year one ($900 of medication plus about $825 of membership after the free first month), against $1,188 on Trimi's annual plan. On tirzepatide, Ivim's starting rates total roughly $2,421 against Trimi's $1,500. That is a difference of roughly $500 to $900+ per year — before any plan-length or dose-related increases at Ivim.

What the $74.99/Month Membership Actually Buys

Ivim's membership is not an empty platform fee — it is where most of the program's differentiation lives. Per Ivim's published materials, the membership includes:

For patients who will actually use unlimited visits and coaching — people newer to structured weight management, or who want frequent provider contact during titration — that bundle has real value. For patients who mainly need the medication with standard clinical oversight, it is roughly $900 a year of services they may rarely touch. That is the entire Ivim decision in one sentence: the medication access is broadly comparable across legitimate compounded GLP-1 providers, so you are choosing how much wraparound support to pay for.

What 36,000+ Trustpilot Reviews Say

Ivim's Trustpilot profile is among the strongest in the category: more than 36,000 reviews, a 4.9 rating, and the #1 position in Trustpilot's Weight Loss Service category at the time of our check. The dominant positive themes are consistent — reviewers repeatedly praise individual providers by name for being knowledgeable, unhurried, and personal, and describe the consultation and refill process as smooth.

The critical reviews cluster around a few themes worth knowing before you enroll: difficulty reaching support by phone, billing issues, app glitches (some patients report not being able to see their current dose in the app), and — most notably for a compounded-medication service — complaints about inconsistent information regarding medication potency and pharmacy sourcing after Ivim switched compounding pharmacies for some patients. None of this is unusual at Ivim's scale, but the pharmacy-sourcing thread is the one we would ask about directly before starting: which pharmacy fills your prescription, and what happens to your dose if that pharmacy changes mid-plan.

On balance, the review base points to a company that delivers its core promise well. It is genuinely one of the strongest social-proof cases in compounded GLP-1 telehealth.

Ivim Health: Strengths and Trade-Offs

Ivim Health vs. Trimi: How the Models Differ

Pricing philosophy

Ivim separates the platform from the medication: an upfront-paid medication plan plus a monthly membership. Trimi bundles everything into one flat monthly price — compounded semaglutide at $99/month or compounded tirzepatide at $125/month on the annual plan, covering the medication at every prescribed dose, licensed provider care, and free overnight shipping once compounded. Neither model is dishonest, but they are hard to compare from the headlines alone; the all-in 12-month total is the only fair yardstick.

Commitment structure

This one deserves plain language in both directions. Ivim's compound plans are paid upfront for the multi-month term you pick — 1 to 6 months on its GLP-1 ID program, 6- and 12-month packages on its pricing page — with the membership required for that duration, and Ivim's own FAQ states that cancellation is not available once a program has started. Trimi's $99 and $125 rates are annual-plan pricing — a 12-month commitment, backed by a 6-month money-back promise rather than a cancel-anytime policy. Neither program is a pay-as-you-go subscription; the difference is term length and what protection stands behind it. If you are mid-treatment elsewhere and weighing a move, our guide on switching GLP-1 providers covers how transfers work without interrupting titration.

Support model

Ivim's membership buys breadth: unlimited visits, coaching, community, 24/7 support. Trimi's model is deliberately leaner — licensed provider care through the Arora Health 50-state network, with prescriptions prepared per individual prescription by state-licensed 503A compounding pharmacies (VialsRx, Texas State Board of Pharmacy #35264, and GreenwichRx) and shipped free overnight once compounded. Patients who want a high-touch coaching ecosystem will get more from Ivim; patients who want supervised medication access at the lowest flat price keep roughly $500–$900+ a year at Trimi.

What the medication itself delivers

The clinical evidence in this category comes from trials of the FDA-approved products, not of compounded preparations. In the STEP 1 trial published in the New England Journal of Medicine, semaglutide 2.4 mg produced an average 14.9% body-weight reduction over 68 weeks; in SURMOUNT-1, tirzepatide produced an average 20.9% reduction over 72 weeks at the highest dose. Compounded preparations have not been studied in trials of their own, and individual results vary. The practical point for this comparison: the primary driver of outcomes is the medication and the quality of clinical oversight — the coaching layer is support, not the therapy. Both platforms ship in multi-month supplies; our 3-month supply guide explains how quarterly shipments and beyond-use dates work for compounded vials.

Who Should Choose Which?

The Verdict on Ivim Health in 2026

Ivim Health is one of the most reputable operations in compounded GLP-1 telehealth: a 4.9 Trustpilot rating across 36,000+ reviews, published outcomes research, licensed providers with unlimited visit access, and a genuinely substantial membership bundle. Patients who engage with the coaching and provider-access layer are paying for something real.

The math still has to be faced. At published starting rates, the mandatory $74.99/month membership takes compounded semaglutide to roughly $150/month all-in and tirzepatide to roughly $208/month — roughly $500 to $900+ per year above Trimi's flat $99 and $125 annual-plan pricing. For patients who primarily need supervised medication access, that premium buys services they may not use. Our compounded tirzepatide cost guide and Mochi Health review show the same membership-fee pattern across the category — and the same conclusion: compare 12-month totals, not headlines. Verify current rates with each provider; individual results vary.